5-SENSE Score Validation Study
Launched by DUKE UNIVERSITY · Nov 14, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients aged 15 years or older in whom no direct surgical approach can be offered and who are discussed in the multidisciplinary team discussion
- • availability of complete non-invasive presurgical work-up (including high-resolution MRI according to the in-center epilepsy protocol, video-telemetry with the recording of a minimum of one habitual clinic and EEG seizure, available as original files for review)
- Exclusion Criteria:
- • no telemetry/scalp EEG in center
- • no protocol MRI in center
- • subdural/GRID electrodes
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Durham, North Carolina, United States
Gainesville, Florida, United States
Valencia, , Spain
Melbourne, Victoria, Australia
Brisbane, , Australia
Melbourne, , Australia
Boston, Massachusetts, United States
Pittsburgh, Pennsylvania, United States
Salzburg, , Austria
Dalhousie, Nova Scotia, Canada
London, Ontario, Canada
Brno, , Czechia
Aarhus, , Denmark
Grenoble, , France
Marseille, , France
Erlangen, , Germany
Freiburg, , Germany
Kyoto, , Japan
Bucharest, , Romania
Lausanne, , Switzerland
London, , United Kingdom
Brisbane, , Australia
Patients applied
Trial Officials
Birgit Frauscher, MD PD
Principal Investigator
Duke University
Alexandra Astner-Rohracher
Principal Investigator
Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported